In-silico molecular docking, ADME study, and molecular dynamic simulation of new azetidin-2-one derivatives with antiproliferative activity

Yıl 2025, Cilt: 9 Sayı: 1, 29 - 40

Aya Ahmed , Monther Faisal

https://doi.org/10.33435/tcandtc.1498365

Öz

Over the past two decades, protein kinase has been a heavily studied target in the development of new anti-proliferative medications. Heterocyclic systems have been identified as the preferred scaffold because of their wide range of biological properties. In this research, the objective was to design and develop fifteen novel azetidin-2-one derivatives and assess their cytotoxic potential as inhibitors of the epidermal growth factor receptor, which is considered one of the key factors influencing cell growth and proliferation. The crystal structure of inactive EGFR tyrosine kinase domain ligand erlotinib from protein data bank was retrieved in order to be docked with our proposed azetidine-2-one derivatives to evaluate their activity as anti-proliferative agents. In this article, an in-silico molecular docking approach proposes that these azetidine-2-one derivatives have satisfactory binding contact with the erlotinib binding site. Although, three compounds have been identified as the most powerful as they have PLP fitness scores of (77.79, 76.68 and 71.46), respectively, while the reference ligand’s fitness score was (71.94). Additionally, all of our derivatives have satisfied the Swiss-ADME parameters, indicating that they may be orally active compounds. In conclusion, two compounds (A-2 and A-8) have better PLP fitness, and one (A-14) has a comparable score in comparison to the reference ligand, at the active site of epidermal growth factor receptor. indicating that the novel azetidine-2-one derivatives have shown interesting results and could be used as model compounds to create novel anti-proliferative drugs. However, more pharmacological evaluation is needed.

Anahtar Kelimeler

Azetidin-2-one, imidazole, EGFR inhibitors, anti-proliferative, molecular dynamic simulation.

Proje Numarası

1

Teşekkür

thanks to Mustansiriyah University/ College of Pharmacy

Kaynakça

• [1] Gümüş, Mehmet, et al. “Recent Advances of Thiazole Hybrids in Biological Applications.” Future Medicinal Chemistry 11(15) (2019) 1979–1998.
• [2] Asquith CR, Laitinen T, Bennett JM, et al. Identification and Optimization of 4‐Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase. ChemMedChem 13(1) (2018) 48-66.
• [3] Zhao J, Li W, Ma R, Chen S, Ren S, Jiang T. Design, synthesis and DNA interaction study of new potential DNA bis-intercalators based on glucuronic acid. Int J Mol Sci 14(8) (2013) 16851-16865.
• [4] Mišković K, Bujak M, Baus Lončar M, Glavaš-Obrovac L. Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs. Arh Hig Rada Toksikol 64(4) (2013) 593-601.
• [5] Sahu U, Sidhar H, Ghate PS, Advirao GM, Raghavan SC, Giri RK. A novel anticancer agent, 8-methoxypyrimido [4′, 5′: 4, 5] thieno (2, 3-b) quinoline-4 (3H)- one induces neuro 2a neuroblastoma cell death through p53-dependent, caspasedependent and-independent apoptotic pathways. PLoS One 8(6) (2013) e66430.
• [6] Ghorab MM, Ragab FA, Heiba HI, Nissan YM, Ghorab WM. Novel brominated quinoline and pyrimidoquinoline derivatives as potential cytotoxic agents with synergistic effects of γ-radiation. Arch Pharm Res 35(8) (2012) 1335-1346.
• [7] Chen YF, Lin YC, Morris‐Natschke SL, et al. Synthesis and SAR studies of novel 6, 7, 8‐substituted 4‐substituted benzyloxyquinolin‐2 (1H)‐one derivatives for anticancer activity. Br J Pharmacol 172(5) (2015) 1195-1221.
• [8] Duan Y-T, Man R-J, Tang D-J, et al. Design, synthesis and antitumor activity of novel link-bridge and b-ring modified combretastatin a-4 (ca-4) analogues as potent antitubulin agents. Sci Rep 6 (2016) 25387.
• [9] Wang Y, Zhang H, Gigant B, et al. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. FEBS J 283(1) (2016) 102-111.
• [10] Blume-Jensen, P., and Hunter, T. Oncogenic kinase signalling. Nature 411(6835) (2001) 355–365.
• [11] Syniugin AR, Ostrynska OV, Chekanov MO, et al. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2. J Enzyme Inhib Med Chem 31(sup4) (2016) 160-169.
• [12] Morin RB, Gorman M (eds) Chemistry and biology of β-lactam antibiotics. Academic Press, New York vol 1-3(1982)
• [13] Antar A. Abdelhamid, S.K. Mohamed, A.M. Maharramov, A.N. Khalilov, & M.A. Allahverdiev. Facile and efficient synthesis of acridinediones from primary amino alcohols via three-component condensation reactions assisted by microwave irradiation. Journal of Saudi Chemical Society 18(5) (2014) 474–478.
• [14] D.A. Burnett, M.A. Caplen Jr., H.R. Davis, R.E. Burrrier, J.W. Clader. 2-Azetidinones as inhibitors of cholesterol absorption. J Med Chem 37(12) (1994) 1733-1736.
• [15] Bergman M, Morales H, Mellars L, et al. The clinical development of a novel cholesterol absorption inhibitor [abstract]. Proceedings of the XII International Symposium on Drugs Affecting Lipid Metabolism. Houston (TX). Houston (TX): Baylor College of Medicine 5 (1995)
• [16] Slusarchyk WA, Bolton SA, Hartl KS, Huang M-H, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Sutton JC, Treuner U, Zahler R, Zhao G, Bisacchi GS. Synthesis of potent and highly selective inhibitors of human tryptase. Bioorg Med Chem Lett 12(21) (2002) 3235–3238.
• [17] Ameya A. Chavan and Nandini R. Pai. Synthesis and biological Activity of N-substituted-3- chloro-2-azetidinones, Molecules 12(11) (2007) 2467-2477.
• [18] Freddy H. Havaldar and Sushil Kumar J. Mishra. Synthesis of some azetidi-2-ones and thiazolidin4-ones as potential antimicrobial Agents, Indian J. Heterocyclic Chemistry 13(3) (2004) 197-200.
• [19] Monther F. Mahdi, Rafah Fadhel Al-Smaism, and Ammar Ihsan Mahmood. "Synthesis, Characterization of Some New 2-Azetidinone Derivatives." Al Mustansiriyah Journal of Pharmaceutical Sciences 15 (2015) 21-28.‏‏
• [20] Jubie S, Gowramma B, Nitin K. Muthal, Kalirajan R, Gomathi S and Elango K. Synthesis and Antimicrobial Evaluation of some 2- Azetidinone derivatives, International Journal of Chem Tech Research 1(2) (2014) 153-157.
• [21] H. Staudinger, Zur kenntniss der ketene, Diphenylketen Justus Liebigs Ann. Chem 356(1-2) (1907) 51–123.
• [22] Ali R, Mirza Z, Ashraf GM, et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res 32 (7) (2012) 2999–3005.
• [23] P. Gupta, S. Hameed, R. Jain. Ring-substituted imidazoles as a new class of anti-tuberculosis agents. European Journal of Medicinal Chemistry 39(9) (2004) 805– 814.
• [24] Ayca Tas, Burak Tüzün, Ali N. Khalilov, Parham Taslimi, Tugba Ağbektas, & Nese Keklikcioglu Cakmak. In vitro cytotoxic effects, in silico studies, some metabolic enzymes inhibition, and vibrational spectral analysis of novel β-amino alcohol compounds. Journal of Molecular Structure 1273(2023) 134282.
• [25] Khalilov, A.N.; Tüzün, B.; Taslimi, P.; Tas, A.; Tuncbilek, Z.; Cakmak, N.K. Cytotoxic effect, spectroscopy, DFT, enzyme inhibition, and moleculer docking studies of some novel mesitylaminopropanols: Antidiabetic and anticholinergics and anticancer potentials. J. Mol. Liq. 344 (2021) 117761.
• [26] Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins: Struct Funct Bioinform 65(1) (2006) 15–26.
• [27] Klebe G. Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov Today 11(13-14) (2006) 580-94.
• [28] Prasanna S, Doerksen RJ. Topological polar surface area: a useful descriptor in 2D-QSAR. Curr Med Chem 16(1) (2009) 21-41.
• [29] Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14(5) (1997) 568-71.
• [30] Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the rule of 5 and drugability. Adv Drug Deliv Rev. 101 (2016) 89-98.